Michigan Drug Discovery has awarded pilot funding to projects working on innovative approaches to treat fibrotic diseases, neurodegenerative disorders, diverticulitis, autoimmune diseases and several forms of cancer.
A new study finds that U-M-designed compounds led to significantly smaller, slower growing tumors.
President Mark Schlissel’s Biosciences Initiative is offering a new funding opportunity to improve core research resources across the University of Michigan.
Michigan Drug Discovery has awarded early-stage funding for five new projects by faculty from across U-M, with the the goals of discovering new drugs for treating cancer, rheumatoid arthritis, and heart disease and creating new non-opioid painkillers.
The Regents of the University of Michigan (U-M) will expand the U-M Biomedical Seed Fund that provides equity-based investments in U-M life science spin outs.
Three projects selected for funding from a highly competitive field
In a reflection of the changing landscape for academic drug discovery at the University of Michigan, the Center for the Discovery of New Medicines will now be known as Michigan Drug Discovery. Along with the change in name, comes a shift in direction, scope and emphasis.
University of Michigan researchers have developed a new building block that can serve as a safer alternative for the development of new medicines.
Expansion of natural products drug discovery and building a drug repurposing library among $45 million in projects funded by the U-M Biosciences Initiative.
A new study in mice finds that absence of a regulatory brain protein could hold the key to stimulating healthy weight loss.
The University of Michigan Center for the Discovery of New Medicines has awarded early-stage funding for six new drug discovery projects by faculty from across U-M.
The Association of American Cancer Institutes has established the Champion for Cures Award to recognize individuals who demonstrate significant leadership in supporting efforts to cure cancer and in inspiring others to do the same. The inaugural award will be presented to Richard and Susan Rogel, in recognition of their generous gift to the University of Michigan Rogel Cancer Center, which was renamed in their honor.
A new drug in development using a dual inhibitor technology for Triple Negative Breast Cancer (TNBC), the only subset of breast cancers that doesn’t have an FDA-approved targeted therapy, was chosen by a panel of investors as the winning project at Fast Forward Medical Innovation’s 2018 Biomedical Innovation Cup on May 16.
The University of Michigan Center for the Discovery of New Medicines has awarded early-stage funding for seven new drug discovery projects by faculty from across U-M.
Cancerous cells often activate telomerase, causing the cells to divide ceaselessly, a hallmark of cancer. University of Michigan researchers have identified a region on a protein called TPP1 that binds this enzyme, which could provide a target for anticancer drugs.